Satraplatin is under clinical development by Dayton Therapeutics and currently in Phase III for T-Cell Lymphomas. According to GlobalData, Phase III drugs for T-Cell Lymphomas have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Satraplatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Satraplatin overview

Satraplatin is under development for the treatment of primary CNS lymphoma and T-cell lymphoma. The drug candidate is a fourth-generation orally bioavailable precision platinum compound. It is being developed based on Artificial Intelligence (AI) platform.

Dayton Therapeutics overview

Dayton Therapeutics (Dayton) is a clinical oncology company that develops compounds for the treatment of cancer indications with limited therapeutic options. Dayton is headquartered in Zug, Switzerland.

For a complete picture of Satraplatin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.